|View printer-friendly version|
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 8457858. A live webcast of the presentation will be available on the Investors & Media section of the
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 (also known as Cas12a) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Mark Mullikin(617) 401-9083 email@example.com Media Cristi Barnett(617) 401-0113 firstname.lastname@example.org
Source: Editas Medicine, Inc.